

Women Infertility - Pipeline Review, H2 2020

https://marketpublishers.com/r/WD02795B1ABEN.html Date: September 2020 Pages: 232 Price: US\$ 2,000.00 (Single User License) ID: WD02795B1ABEN

Abstracts

Women Infertility - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2020, provides an overview of the Women Infertility (Women's Health) pipeline landscape.

Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,



Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 21, 16, 1, 2, 22, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).

The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)



and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction Women Infertility - Overview Women Infertility - Therapeutics Development Women Infertility - Therapeutics Assessment Women Infertility - Companies Involved in Therapeutics Development Women Infertility - Drug Profiles Women Infertility - Dormant Projects Women Infertility - Discontinued Products Women Infertility - Product Development Milestones Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Women Infertility, H2 2020 Number of Products under Development by Companies, H2 2020 Number of Products under Development by Universities/Institutes, H2 2020 Products under Development by Companies, H2 2020 Products under Development by Universities/Institutes, H2 2020 Number of Products by Stage and Target, H2 2020 Number of Products by Stage and Mechanism of Action, H2 2020 Number of Products by Stage and Route of Administration, H2 2020 Number of Products by Stage and Molecule Type, H2 2020 Women Infertility - Pipeline by Adynxx Inc, H2 2020 Women Infertility - Pipeline by AlphaMab Co Ltd, H2 2020 Women Infertility - Pipeline by Amega Biotech, H2 2020 Women Infertility - Pipeline by Anelleo Inc, H2 2020 Women Infertility - Pipeline by Aprilbio Co Ltd, H2 2020 Women Infertility - Pipeline by Aptorum Group Ltd, H2 2020 Women Infertility - Pipeline by ARTham Therapeutics Inc, H2 2020 Women Infertility - Dormant Projects, H2 2020 Women Infertility - Discontinued Products, H2 2020




List Of Figures

LIST OF FIGURES

Number of Products under Development for Women Infertility, H2 2020 Number of Products under Development by Companies, H2 2020 Number of Products under Development by Universities/Institutes, H2 2020 Number of Products by Top 10 Targets, H2 2020 Number of Products by Stage and Top 10 Targets, H2 2020 Number of Products by Top 10 Mechanism of Actions, H2 2020 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020 Number of Products by Routes of Administration, H2 2020 Number of Products by Stage and Routes of Administration, H2 2020 Number of Products by Top 10 Molecule Types, H2 2020 Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Adynxx Inc AlphaMab Co Ltd Amega Biotech Anelleo Inc Aprilbio Co Ltd Aptorum Group Ltd **ARTham Therapeutics Inc** ASKA Pharmaceutical Co Ltd Auritec Pharmaceuticals Inc Bayer AG Beijing Fogangren Bio-Pharm Tech Co Ltd Beijing SL Pharmaceutical Co Ltd Bharat Serums And Vaccines Ltd **Bol Pharma** Bopin (Shanghai) Biomedical Technology Co Ltd Chugai Pharmaceutical Co Ltd **Context Therapeutics LLC** Daewoong Pharmaceutical Co Ltd ElexoPharm GmbH Enteris BioPharma Inc Eurofarma Laboratorios SA





Evestra Inc Evotec SE FemmePharma Global Healthcare Inc Ferring International Center SA Ferring Pharmaceuticals Inc Forendo Pharma Ltd GeneScience Pharmaceuticals Co Ltd Genome & Co **Glycotope GmbH** Igenomix SL Igyxos SA Immunitor Inc Isifer AB Jiangsu Hengrui Medicine Co Ltd Kissei Pharmaceutical Co Ltd LG Chem Ltd Livzon Pharmaceutical Group Co Ltd Luye Pharma Group Ltd Mitsubishi Tanabe Pharma Corp **Myovant Sciences Ltd** Navad Life Sciences Pte Ltd Nippon Shinyaku Co Ltd NutriBand Inc **ObsEva SA Oxolife SL** Pangen Biotech Inc Park Active Molecules Philogen SpA **Predictive Therapeutics LLC** PregLem SA **Reven Pharmaceuticals Inc** Richter Gedeon Nyrt Shanghai Jing Ze Biotechnology Co Ltd Shenzhen Salubris Pharmaceuticals Co Ltd Suzhou JiSheng Pharmaceutical Co Ltd SYNG Pharmaceuticals Inc Takeda Pharmaceutical Co Ltd **Temple Therapeutics BV** TiumBio Co Ltd



Trophogen Inc ValiRx Plc Viramal Ltd Xbrane Biopharma AB



I would like to order

Product name: Women Infertility - Pipeline Review, H2 2020 Product link: https://marketpublishers.com/r/WD02795B1ABEN.html Price: US\$ 2,000.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/WD02795B1ABEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970